Streetbeat News

NVCT

Nuvectis Pharma, Inc.

https://www.nuvectis.com

Industry

Biotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Open

8.23

Mkt cap

156M

Volume

303K

High

8.85

P/E Ratio

-6.47

52-wk high

12.10

Low

8.02

Div yield

N/A

52-wk low

5.85

In Thursday's pre-market session, several healthcare stocks showed significant movement. Aptorum Gr, Nuvectis Pharma, and Bright Green were among the top gainers, with shares increasing by 47.1%, 23.65%, and 20.99% respectively. On the losing side, Spruce Biosciences saw a dramatic drop of 78% following its Q4 earnings report. Other notable decliners include Kintara Therapeutics and Nuvation Bio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 1:06 pm

Nuvectis Pharma, Inc. (NVCT) reported a fiscal year 2023 EPS of $(1.43), an improvement from $(1.51) in the previous year. The company saw an increase in both research and development and general and administrative expenses, leading to a larger operating loss of $(22,897) thousand compared to $(19,234) thousand in 2022. Despite this, the net loss was slightly reduced to $(22,260) thousand from $(19,085) thousand, attributed to an increase in finance income.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:21 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Celularity (CELU) saw a 44.7% increase, while NovoCure (NVCR) rose by 24.15%. Jasper Therapeutics (JSPR) and Nuvectis Pharma (NVCT) also saw upward movements of 22.18% and 14.85%, respectively. Bullfrog AI Hldgs (BFRG) and Venus Concept (VERO) stocks rose by 14.74% and 14.28%. On the downside, Aravive (ARAV) dropped by 43.2%, Processa Pharma (PCSA) by 26.35%, and ZyVersa Therapeutics (ZVSA), 60 Degrees (SXTP), Cano Health (CANO), and MAIA Biotechnology (MAIA) also experienced declines.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 5:31 pm

Nuvectis Pharma reported Q3 losses of $(0.37) per share, missing the analyst consensus estimate of $(0.34) by 8.82 percent. This is an 11.9 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:10 pm

Nuvectis Pharma (NASDAQ:NVCT) reported Q3 earnings, missing estimated earnings by 8.82% with an EPS of $-0.37 versus an estimate of $-0.34. Revenue was down $0 from the same period last year. Last quarter, the company also missed on EPS by $0.09, which was followed by a 0.4% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 1:10 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Nkarta, Assembly Biosciences, Olink Holding, Anebulo Pharmaceuticals, Moleculin Biotech, and OpGen saw their shares rise, while Evelo Biosciences, Monte Rosa Therapeutics, Celcuity, Tiziana Life Sciences, Better Therapeutics, and Nuvectis Pharma experienced a decline in their stock prices.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 5:31 pm

Nuvectis Pharma has announced upcoming presentations for its products NXP800 and NXP900. The company, which trades under the symbol NVCT, is expected to provide updates on these products.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:01 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Nuvectis Pharma (NASDAQ:NVCT) and maintained a $21 price target.

Portfolio Pulse from Benzinga Newsdesk

September 15, 2023 | 10:10 am

Nuvectis Pharma, Inc. (NASDAQ:NVCT) has initiated a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family. The study aims to evaluate the safety, tolerability and pharmacokinetic properties of NXP900 in patients with advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:02 pm

The FDA has granted Orphan Drug Designation to Nuvectis Pharma's NXP800 for the treatment of Cholangiocarcinoma. This designation provides certain benefits including tax credits, market exclusivity, and waiver of certain fees.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 12:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.